Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
- None.
- None.
Entering a new stock exchange often signals a company's growth and potential for increased liquidity. Eupraxia Pharmaceuticals' Nasdaq listing could attract a broader investor base, particularly in the U.S., where biotech companies often find a more active trading environment. This move may also imply Eupraxia's ambition to expand its visibility and credibility within the international investment community.
However, it's essential to monitor the stock's performance post-listing. New listings can experience volatility as the market adjusts to the additional shares and new investor attention. The company's performance on the Toronto Stock Exchange could serve as a benchmark for its potential trajectory on Nasdaq.
Investors should consider the implications of cross-listing, such as increased regulatory scrutiny and the costs associated with maintaining listings on multiple exchanges. While the listing itself is a positive development, it's the company's underlying fundamentals and progress in its clinical programs that will ultimately drive long-term value.
Eupraxia's proprietary Diffusphere™ technology is a differentiator in the crowded biotech space. Optimizing drug delivery is a significant challenge in the industry and Eupraxia's technology could potentially address this, offering a competitive edge. Investors should assess the company's intellectual property position and any data supporting the efficacy of its technology.
Furthermore, the biotech sector is highly dependent on successful clinical trial outcomes. Eupraxia's clinical-stage status means that it's at a critical juncture where positive trial results could significantly enhance its valuation, while setbacks could have the opposite effect. The company's ability to navigate the complex regulatory landscape will be a key factor in its success on the Nasdaq.
Long-term investors will be interested in the company's pipeline and the addressable market for its applications. If Eupraxia can secure FDA approval for its products, it could tap into lucrative markets, but this is often a lengthy and uncertain process.
The Company's shares also continue to trade on the Toronto Stock Exchange under the ticker symbol "EPRX".
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable PK profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods.
Eupraxia recently completed a Phase 2b clinical trial (SPRINGBOARD) for its lead product candidate, EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. The trial met its primary endpoint and three of the four secondary endpoints. Eupraxia has expanded the EP-104 platform into gastrointestinal disease with the Phase 1b/2a RESOLVE trial for treating eosinophilic esophagitis. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
This news release includes forward-looking statements and forward–looking information within the meaning of applicable securities laws. Often, but not always, forward–looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements in this news release include statements regarding Eupraxia's listing on the Nasdaq and the potential of Eupraxia's product candidates. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward–looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward–looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward–looking statement or information can be guaranteed. Except as required by applicable securities laws, forward–looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward–looking statement or information, whether as a result of new information, future events or otherwise.
View original content:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-begins-trading-on-nasdaq-today-302109044.html
SOURCE Eupraxia Pharmaceuticals Inc.
FAQ
When did Eupraxia Pharmaceuticals Inc. start trading on Nasdaq?
What is the ticker symbol for Eupraxia Pharmaceuticals Inc. on Nasdaq?
What technology does Eupraxia Pharmaceuticals Inc. leverage for drug delivery optimization?
Where else can Eupraxia Pharmaceuticals Inc. shares be traded?
